190 related articles for article (PubMed ID: 34484797)
21. Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma.
Dimou A; Barron G; Merrick DT; Kolfenbach J; Doebele RC
BMC Cancer; 2020 Mar; 20(1):177. PubMed ID: 32131760
[TBL] [Abstract][Full Text] [Related]
22. Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report.
Adachi Y; Yanagimura N; Suzuki C; Ootani S; Tanimoto A; Nishiyama A; Yamashita K; Ohtsubo K; Takeuchi S; Yano S
BMC Cancer; 2020 Feb; 20(1):156. PubMed ID: 32093631
[TBL] [Abstract][Full Text] [Related]
23. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
24. [Strategic Exploration of Targeted Therapy for BRAF Non-V600E Mutant Lung Cancer].
Zhang H; Gao J; Guo W; Yu B; Yang H; Liu Y
Zhongguo Fei Ai Za Zhi; 2022 Feb; 25(2):86-91. PubMed ID: 35224961
[TBL] [Abstract][Full Text] [Related]
25. Cerebral infarction after treatment with dabrafenib plus trametinib for BRAF-V600E-positive non-small cell lung cancer: A case report.
Taniguchi Y; Tamiya A; Yanagisawa A; Shimaya M; Kawakami M; Inagaki Y; Saijo N; Matsuda Y; Okishio K
Thorac Cancer; 2023 May; 14(13):1201-1203. PubMed ID: 36935386
[TBL] [Abstract][Full Text] [Related]
26. Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models.
Zhou X; Zhao J; Zhang JV; Wu Y; Wang L; Chen X; Ji D; Zhou GG
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578339
[TBL] [Abstract][Full Text] [Related]
27. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
[TBL] [Abstract][Full Text] [Related]
28. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
Wang H; Quan H; Lou L
Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
[TBL] [Abstract][Full Text] [Related]
29. BRAF
Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
[TBL] [Abstract][Full Text] [Related]
30. Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation.
Qu J; Shen Q; Li Y; Kalyani FS; Liu L; Zhou J; Zhou J
Front Oncol; 2022; 12():911303. PubMed ID: 35814395
[TBL] [Abstract][Full Text] [Related]
31. BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer.
Nguyen-Ngoc T; Bouchaab H; Adjei AA; Peters S
J Thorac Oncol; 2015 Oct; 10(10):1396-403. PubMed ID: 26301799
[TBL] [Abstract][Full Text] [Related]
32. MAP2K1 K57N Conferred an Acquired Resistance to Furmonertinib, Dabrafenib and Trametinib Combined Therapy in Advanced Lung Adenocarcinoma with EGFR Mutation and BRAF V600E.
Tan X; Wu Z; Chen M
Onco Targets Ther; 2024; 17():307-312. PubMed ID: 38617091
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in
Grenda A; Krawczyk P; Targowska-Duda KM; Kieszko R; Paśnik I; Milanowski J
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674722
[TBL] [Abstract][Full Text] [Related]
34. Dabrafenib and trametinib administration in patients with
Shimoi T; Sunami K; Tahara M; Nishiwaki S; Tanaka S; Baba E; Kanai M; Kinoshita I; Shirota H; Hayashi H; Nishida N; Kubo T; Mamesaya N; Ando Y; Okita N; Shibata T; Nakamura K; Yamamoto N
EClinicalMedicine; 2024 Mar; 69():102447. PubMed ID: 38333370
[TBL] [Abstract][Full Text] [Related]
35. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
Long GV; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Grob JJ; Chiarion Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JB; Hansson J; Utikal J; Ferraresi V; Kovalenko N; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; DeMarini DJ; Irani JG; Casey M; Ouellet D; Martin AM; Le N; Patel K; Flaherty K
N Engl J Med; 2014 Nov; 371(20):1877-88. PubMed ID: 25265492
[TBL] [Abstract][Full Text] [Related]
36. Targeting BRAF mutations in non-small cell lung cancer.
O'Leary CG; Andelkovic V; Ladwa R; Pavlakis N; Zhou C; Hirsch F; Richard D; O'Byrne K
Transl Lung Cancer Res; 2019 Dec; 8(6):1119-1124. PubMed ID: 32010589
[TBL] [Abstract][Full Text] [Related]
37. Metastatic BRAF V600E-Mutated Adenocarcinoma of the Lung Presenting as Extreme Neutrophilia and Eosinophilia.
Muhammad A; Nair HK; Tulpule S; Khan A
Cureus; 2021 Oct; 13(10):e18930. PubMed ID: 34812314
[TBL] [Abstract][Full Text] [Related]
38. Unbiased Proteomic and Phosphoproteomic Analysis Identifies Response Signatures and Novel Susceptibilities After Combined MEK and mTOR Inhibition in BRAF
Maxwell MJ; Arnold A; Sweeney H; Chen L; Lih TM; Schnaubelt M; Eberhart CG; Rubens JA; Zhang H; Clark DJ; Raabe EH
Mol Cell Proteomics; 2021; 20():100123. PubMed ID: 34298159
[TBL] [Abstract][Full Text] [Related]
39. Adverse Event Management in Patients with
Chalmers A; Cannon L; Akerley W
Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
